PennyTrader.com Trade Alert for today is Genesis Biopharma, Inc. (OTCBB: GNBP)
Genesis Biopharma, Inc. (OTCBB: GNBP) is developing autologous cell therapies for the treatment of cancer.
Their lead product candidate, Cōntego™, is an autologous cell therapy using tumor infiltrating lymphocytes (TILs) indicated for the treatment of metastatic melanoma. Cōntego™ is being developed as a ready-to-infuse autologous cell therapy product. Following resection of the patient’s tumor, TILs are isolated from the resected tumor, and expanded in vitro to several billion cells. The expanded TILs are then infused into the patient where they attack the melanoma tumors regardless of their location in the body.
Cōntego™ is based on the adoptive cell therapy regimen using tumor infiltrating lymphocytes invented by Dr. Steven A. Rosenberg, Chief, Surgery Branch, Center for Cancer Research, National Cancer Institute for the treatment of metastatic melanoma. Dr. Rosenberg’s adoptive cell therapy is presently available as a physician-sponsored investigational therapy for the treatment of Stage IV metastatic melanoma at the National Cancer Institute, MD Anderson Cancer Center, and the H. Lee Moffitt Cancer & Research Institute.
March 22 - Genesis Biopharma Names Biotech Industry Veteran Hans E. Bishop as Executive Chairman of the Board
Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced that Hans E. Bishop has been named Executive Chairman of the Company's Board of Directors. Mr. Bishop has served as a Director of the Company since January 2012. Anthony J. Cataldo, formerly the Chairman of the Board, will remain as a Director of the Company.
"It is with great pleasure that we welcome Hans as our Executive Chairman. Since joining our Board earlier this year, Hans has played an integral role in our strategic planning and his background makes him ideally suited to guide the Company as we advance our clinical programs for Contego™, our ready-to-infuse adoptive cell therapy using TILs, to treat Stage IV metastatic melanoma," said Mr. Cataldo. "To support our business plan we have been expanding our leadership with talented, experienced professionals. The addition of Hans as our Executive Chair further enhances this dynamic team as he is a proven leader with an impressive track record of enhancing operational and financial results."
To View Full Company Profile: CLICK HERE
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at email@example.com.
Disclosure: PennyTrader and affiliates expect to be paid four thousand dollars by a third party for GNBP promoitonal email coverage
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer Click Here